OncoMed Signs Second Cancer Stem Cell Partner; This Time It's Bayer
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with Bayer to discover and develop Wnt pathway therapies follows 2007 deal with GSK focused on Notch pathway.
You may also be interested in...
Verastem Joins The Public Markets With A Strong IPO
Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.
At PSA, Meet The New Deal-Makers (Part 2)
At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.
At PSA, Meet The New Deal-Makers (Part 2)
At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.